SCHEMBL2011766

SCHEMBL2011766

CCCC(=O)C(=O)Oc1c(CCN(CCC)CCC)cccc1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.40
DRD2 P14416 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ADRA2B P18089 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
HTR2A P28223 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011930 0.87 HTR1A (0.43) HTR1ADRD2KDM4ELMNACHRM2
Hydrochloric Acid SCHEMBL2012931 0.86 HTR1A (0.42) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL3841214 0.75 TDP1 (0.51) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL7292776 0.75 HTR1A (0.46) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL2011929 0.75 HTR1A (0.44) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL2011768 0.74 DRD2 (0.43) HTR1ADRD2KDM4ELMNAMAPK1
Hydrochloric Acid SCHEMBL2012002 0.74 TDP1 (0.50) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL10867623 0.74 HTR1A (0.45) HTR1ADRD2KDM4ELMNACHRM2
Hydrochloric Acid SCHEMBL2012929 0.74 HTR1A (0.43) HTR1ADRD2KDM4ELMNACHRM2
SCHEMBL13618631 0.73 HTR1A (0.43) HTR1ADRD2KDM4ELMNACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513055-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF Pharmathen S.A. (GR) 2012-10-24 EP claimed
US-20120253051-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF PHARMATHEN S.A. (GR) 2012-10-04 US claimed
WO-2011072704-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF PHARMATHEN S.A. (GR) 2011-06-23 WO claimed
US-7619095-B2 Process for the preparation of indolone derivative ALEMBIC LIMITED (IN) 2009-11-17 US claimed
EP-1848691-B1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LTD (IN) 2009-11-11 EP claimed
US-20080262244-A1 Process for the Preparation of Indolone Derivative ALEMBIC LIMITED (IN) 2008-10-23 US claimed
EP-1848691-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE Alembic Limited (IN) 2007-10-31 EP claimed
WO-2006123356-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LIMITED (IN) 2006-11-23 WO claimed
CN-116262706-A Preparation process of ropinirole intermediate 浙江华海药业股份有限公司 2023-06-16 CN disclosed
CN-116262706-A Preparation process of ropinirole intermediate 浙江华海药业股份有限公司 2023-06-16 CN disclosed
EP-2513055-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF Pharmathen S.A. (GR) 2012-10-24 EP disclosed
US-20120253051-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF PHARMATHEN S.A. (GR) 2012-10-04 US disclosed
WO-2011072704-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF PHARMATHEN S.A. (GR) 2011-06-23 WO disclosed
US-7619095-B2 Process for the preparation of indolone derivative ALEMBIC LIMITED (IN) 2009-11-17 US disclosed
EP-1848691-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE Alembic Limited (IN) 2007-10-31 EP disclosed
WO-2006123356-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LIMITED (IN) 2006-11-23 WO disclosed
EP-0113964-B1 4-AMINOALKYL-2(3H)-INDOLONES SMITHKLINE BECKMAN CORPORATION (US) 1986-10-22 EP disclosed
US-4588740-A Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones SMITHKLINE BECKMAN CORPORATION (US) 1986-05-13 US disclosed
EP-0113964-A1 4-Aminoalkyl-2(3H)-indolones SMITHKLINE BECKMAN CORPORATION (US) 1984-07-25 EP disclosed
US-4452808-A HYPOTENSIVE AGENTS SMITHKLINE BECKMAN CORPORATION (US) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262244-A1 Process for the Preparation of Indolone Derivative HTR3C, HTR3B, HTR1B HTR1A 16/4885DRD2 48/4885KDM4E 627/4885
US-20120253051-A1 PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF PRLHR, ADCYAP1R1, REN HTR1A 792/4885DRD2 26/4885KDM4E 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.